Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

LEAPS vaccine reduces disease severity in RA models
April 2017
SHARING OPTIONS:

VIENNA—In recent months, CEL-SCI Corporation shared preclinical data supporting CEL-4000, an investigational new drug candidate developed using its patented Ligand Epitope Antigen Presentation System (LEAPS), as a therapeutic vaccine for treating rheumatoid arthritis (RA). The study looked at the efficacy of the LEAPS vaccine in the Proteoglycan (PG) induced arthritis (PGIA) and the closely related recombinant huG1 domain of PG (GIA) in animal models of RA that had a dominant T helper 1 cytokine profile. The mice treated with the LEAPS vaccine saw lower disease severity compared to controls. In the PGIA model, the reduced disease severity after vaccination corresponded with up-regulation of T regulatory cells and Th2 cytokines (IL-10, IL-4 and TGF-β), as well as reduced proliferation of PG specific T lymphocytes and decreased production of Th1 and Th17 cytokines (IFN-γ and IL-17).
 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.